Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2017 07/24/2017 07/25/2017 07/26/2017 07/27/2017 Date
282.92(c) 284.7(c) 282.96(c) 295.61(c) 287.95(c) Last
985 437 1 476 166 3 110 019 3 014 605 1 706 682 Volume
+0.53% +0.63% -0.61% +4.47% -2.59% Change
More quotes
Financials ($)
Sales 2017 11 816 M
EBIT 2017 6 128 M
Net income 2017 3 866 M
Debt 2017 1 227 M
Yield 2017 -
Sales 2018 12 335 M
EBIT 2018 6 526 M
Net income 2018 4 465 M
Finance 2018 899 M
Yield 2018 -
P/E ratio 2017 16,40
P/E ratio 2018 13,91
EV / Sales2017 5,39x
EV / Sales2018 4,99x
Capitalization 62 501 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
07/27 ABARCA HEALTH : And Biogen Announces Innovative Value-Based Contract For Multipl..
07/27 BIOGEN : Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem..
07/27 BIOGEN : Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Ann..
07/25 BIOGEN : Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Rev..
07/25 BIOGEN : Investor Network: Biogen Inc. to Host Earnings Call
07/24 BIOGEN : Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operati..
07/14 BIOGEN : to Present Data at Alzheimer's Association International Conference® 20..
07/10 BIOGEN : Appoints Amy Chevalier Efantis Vice President of Government Affairs
06/28 BIOGEN : Appoints Catherine Steele Senior Vice President of Corporate Affairs
06/23 BIOGEN : IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Grant..
More news
Sector news : Biopharmaceuticals
07/27 S&P 500 declines with transports; oil extends recent rally
07/27DJADRs End Mostly Lower; Anheuser-Busch InBev, AstraZeneca Trade Actively
07/27 AstraZeneca pain weighs on FTSE, Diageo makes merry after results
07/27 AstraZeneca lung cancer failure sparks 16 percent share fall
07/27DJASTRAZENECA : Shares Dive After Major Setback Over Cancer Drugs -- 3rd Update
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN 
2014Back on a stimulating support
2013The bullish trend is not over
More Strategies
Latest Tweets
03:50aAbarca Health And Biogen Announces Innovative Value-Based Contract For Multip.. 
07/27BRIEF-Abarca Health signs reimbursement contract with Biogen for select produ.. 
07/27William Blair Raises Biogen Q3 2018 Earnings Estimates to $6.17 Per Share (Pr.. 
07/27Jefferies Group LLC Raises Biogen Q4 2017 Earnings Estimates to $5.59 Per Sha.. 
07/2748 hours - $ALXN reboots pipeline https://t.co/IMExwvaP45 $GSK restructure..
20
More tweets
Qtime:137
News from SeekingAlpha
07/26 BIOGEN Q2 2017 RESULTS : Few Steps In The Right Direction
07/26 Biogen Positions Itself For The Future
07/26 2 Cheers For Biogen, Which May Be Good Enough To Allow Alpha
07/25 Nektar Makes A Stride Forward In Resolving Autoimmune Diseases
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 328 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Adriana Karaboutis Executive VP-Technology & Business Solutions
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN13.11%62 501
CSL LIMITED28.04%46 735
ALEXION PHARMACEUTICALS7.13%29 433
GRIFOLS SA21.03%16 773
BIOMARIN PHARMACEUTICAL7.68%15 565
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%4 457